Drugmaker Hospira said Wednesday that it received a warning letter from the Food and Drug Administration regarding poor manufacturing quality at one of its facilities in Australia.
Healthcare supply, analytics and consulting company Premier agreed Tuesday to acquire TheraDoc, a clinical surveillance software company, for $117 million, augmenting Premier's already sizable footprint in the clinical-safety solutions market.
Pharmaceutical and medical-device maker Hospira saw its earnings soar in the second quarter of 2014, thanks mostly to large sales of drugs that have been in short supply.
The American Hospital Association is pushing the Food and Drug Administration to be more aggressive in getting manufacturers of saline and other IV fluids to increase production to alleviate shortages.
A worsening shortage of IV saline solution, one of the most common products used in hospitals, is causing concern among healthcare providers having trouble locating saline products during this increasingly severe flu season.
The FDA is releasing a strategic plan to address the underlying causes of drug shortages, and will launch a new mobile app to alert relevant stakeholders when shortages occur.
ActiveCare, which provides remote health monitoring for diabetes and chronic disease management, has named Jonathan Olson its chief technology officer.
Tim Weaver, an 18-year-old college student who lives in Naperville, Ill., is one of the estimated 30,000 people in the U.S. who rely on intravenous nutrition products to keep them alive.
Hospira said U.S. health regulators raised fresh concerns about the injectable-drugs maker's troubled Rocky Mount, N.C., manufacturing plant, one of its largest production facilities.
Hospira successfully fought off a government request for more details about its prolonged efforts to fix safety problems, a win that highlights the scrutiny of CEO F. Michael Ball's efforts to boost production at the giant medical products maker.
Hospira, a Lake Forest, Ill.-based generic drug manufacturer, said it has acquired an active pharmaceutical ingredient, or API, manufacturing facility from an Indian drug company for $200 million.
The market for infection-control system software is small and is dominated by applications developed specifically for this narrow market niche, but it won't stay that way much longer, according to a report from KLAS Enterprises.